OverviewSuggest Edit

AIM ImmunoTech (formerly known as Hemispherx Biopharma) is an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Its flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3).

TypePublic
Founded1990
HQOcala, US
Websiteaimimmuno.com
Employee Ratings2.1

Latest Updates

Employees (est.) (Feb 2019)31(+24%)
Revenue (FY, 2019)$140 K(-61%)
Share Price (Sept 2020)$2.3 (-10%)
Cybersecurity ratingAMore

Key People/Management at AIM ImmunoTech

Thomas K. Equels

Thomas K. Equels

Executive Vice Chairman, Chief Executive Officer, President
Peter W. Rodino

Peter W. Rodino

Chief Operating Officer, Executive Director for Governmental Relations, General Counsel, Secretary
Ellen Lintal

Ellen Lintal

CFO
Show more

AIM ImmunoTech Office Locations

AIM ImmunoTech has offices in Ocala and New Brunswick
Ocala, US (HQ)
2117 SW Hwy 484
New Brunswick, US
783 Jersey Ave
Show all (2)

AIM ImmunoTech Financials and Metrics

AIM ImmunoTech Revenue

Embed Graph
View revenue for all periods
AIM ImmunoTech's revenue was reported to be $140 k in FY, 2019
USD

Revenue (Q2, 2020)

40.0k

Gross profit (Q2, 2020)

(160.0k)

Gross profit margin (Q2, 2020), %

(400%)

Net income (Q2, 2020)

(3.4m)

EBIT (Q2, 2020)

(3.3m)

Market capitalization (23-Sept-2020)

90.1m

Closing stock price (23-Sept-2020)

2.3

Cash (30-Jun-2020)

33.9m

EV

58.7m
AIM ImmunoTech's current market capitalization is $90.1 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

3.1m2.2m803.0k2.2m2.1m2.4m1.4m299.0k1.5m

Accounts Receivable

24.0k235.0k44.0k

Prepaid Expenses

531.0k322.0k358.0k399.0k335.0k610.0k880.0k848.0k

Current Assets

31.8m44.7m18.6m16.5m10.6m6.9m3.5m3.8m10.4m
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

AIM ImmunoTech Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

AIM ImmunoTech Online and Social Media Presence

Embed Graph

AIM ImmunoTech News and Updates

Thinking about buying stock in AIM ImmunoTech, Rockwell Medical, Transocean, Aurora Cannabis, or Wayfair?

NEW YORK, Sept. 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AIM, RMTI, RIG, ACB, and W. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Soligenix Inc, Ekso Bionics, SINTX Technologies, AIM ImmunoTech, or Nio Inc?

NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNGX, EKSO, SINT, AIM, and NIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Adaptimmune Therapeutics, MEI Pharma, Dynavax Technologies, AIM ImmunoTech, or Meridian Bioscience?

NEW YORK, May 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, MEIP, DVAX, AIM, and VIVO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen® for Use Against the SARS-like Wuhan 2019 Novel Coronavirus

Ampligen® obtained 100% survival rate at clinically achievable human dosage levels for SARS in animal experiments

Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS

Announces new ticker symbol ‘AIM’ effective September 3, 2019 Announces new ticker symbol ‘AIM’ effective September 3, 2019

Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program

OCALA, Fla., June 17, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE American: HEB) issued its quarterly update on the progress of its ongoing clinical trials evaluating Ampligen’s ability to reprogram tumor microenvironments and increase the effectiveness of existing cancer immunotherap…
Show more

AIM ImmunoTech Blogs

AIM ImmunoTech Frequently Asked Questions

  • When was AIM ImmunoTech founded?

    AIM ImmunoTech was founded in 1990.

  • Who are AIM ImmunoTech key executives?

    AIM ImmunoTech's key executives are Thomas K. Equels, Peter W. Rodino and Ellen Lintal.

  • How many employees does AIM ImmunoTech have?

    AIM ImmunoTech has 31 employees.

  • What is AIM ImmunoTech revenue?

    Latest AIM ImmunoTech annual revenue is $140 k.

  • What is AIM ImmunoTech revenue per employee?

    Latest AIM ImmunoTech revenue per employee is $4.5 k.

  • Who are AIM ImmunoTech competitors?

    Competitors of AIM ImmunoTech include Northwest Biotherapeutics, Merrimack Pharmaceuticals and CytomX Therapeutics.

  • Where is AIM ImmunoTech headquarters?

    AIM ImmunoTech headquarters is located at 2117 SW Hwy 484, Ocala.

  • Where are AIM ImmunoTech offices?

    AIM ImmunoTech has offices in Ocala and New Brunswick.

  • How many offices does AIM ImmunoTech have?

    AIM ImmunoTech has 2 offices.